Company intelligence / Profile preview

TScan Therapeutics, Inc.

Waltham, Massachusetts, United Statesglobaldata.com ↗

Ownership: Private
Development stage: Phase 1

Overview

TScan Therapeutics develops engineered T cell receptor therapies targeting both hematologic malignancies and solid tumors. Its lead candidates—TSC‑100 and TSC‑101—are in Phase I trials for AML, MDS, and ALL in the context of allogeneic HCT. The company also has additional preclinical programs focused on expanding its pipeline to other cancers. No pivotal efficacy data have been reported yet; the focus remains on early safety/tolerability and proof-of-concept studies.

Therapeutic areas: OncologyHematology
Modalities: T cell receptor-engineered T cells (TCR-T)Cell therapy
Industry: Biotech

Drug pipeline

18 assets

TSC-101

17 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on TScan Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TScan Therapeutics, Inc..

Explore the full profile